Abstract: TRULI, also known as Lats-IN-1, is a pharmacological inhibitor of the LATS1/2 kinases, which are core components of the highly conserved Hippo signaling pathway. By inhibiting LATS1/2, TRULI prevents the phosphorylation and subsequent degradation of the transcriptional co-activator YAP, leading to its nuclear accumulation and the activation of genes involved in cell proliferation, survival, and plasticity. Recent research highlights its significant potential in stem cell biology, organoid culture, and regenerative medicine. TRULI has demonstrated the ability to promote cardiomyocyte proliferation and improve cardiac function following myocardial infarction. In 3D organoid cultures, it induces the proliferation and colony formation of primary dental epithelial cells, including differentiated ameloblasts. However, its effects are highly context-dependent; for instance, TRULI-mediated YAP activation inhibits the de-differentiation of corneal epithelial cells into limbal stem cells. This review synthesizes current findings on TRULI's pharmacological activity, mechanisms, limitations, and future therapeutic perspectives.
1. Introduction
Tissue homeostasis, injury repair, and organ size control are heavily reliant on the activity of resident somatic stem cells and the precise regulation of cellular proliferation and differentiation. A central regulatory network governing these processes is the evolutionarily conserved Hippo signaling pathway [1][2]. The core of this pathway includes the LATS1 and LATS2 kinases, which act as negative regulators of the downstream effector Yes-associated protein (YAP) [1]. TRULI (Lats-IN-1) is a small-molecule inhibitor specifically designed to target and inhibit LATS1/2 kinases [2]. By modulating the Hippo pathway, TRULI has emerged as a valuable tool in stem cell biology and regenerative medicine, offering a translational approach to manipulate cell fate, enhance tissue regeneration, and study cellular plasticity in various contexts, including cardiac repair, dental epithelial organoid culture, and corneal stem cell dynamics [1][2][3].
2. Pharmacological Activity
TRULI (Lats-IN-1) exhibits diverse pharmacological activities across different tissue types, primarily characterized by its ability to stimulate cell proliferation and modulate cellular plasticity:
Cardiac Regeneration and Protection: In murine models of myocardial infarction (MI), intraperitoneal administration of Lats-IN-1 (1 mg/kg/day) significantly mitigates cardiac dysfunction. It improves left ventricular ejection fraction (EF%) and fractional shortening (FS%), while reducing ventricular dilation and infarct size [2]. The compound promotes the proliferation of cardiomyocytes in both the infarcted and remote zones of the heart and protects these cells from apoptosis, thereby attenuating pathological heart remodeling [2].
Dental Epithelial Stem Cells and Organoids: In the context of 3D organoid culture, TRULI demonstrates the ability to induce cellular plasticity. When primary cells from the murine incisor (both cervical loop progenitor cells and differentiated ameloblasts) are dissociated and cultured in 3D Matrigel, treatment with 10 μM TRULI significantly enhances their proliferation. Notably, it induces spheroid and colony formation in differentiated ameloblasts to a level comparable to that of progenitor cells, indicating that LATS inhibition can unlock proliferative plasticity in differentiated cells when removed from their intact tissue microenvironment [1].
Corneal Epithelial Cell Plasticity: The pharmacological effects of TRULI are highly context-dependent. In the cornea, the de-differentiation of corneal epithelial cells (CECs) into functional limbal epithelial stem cells (LESCs) requires a transient activation followed by a decrease in YAP activity. When TRULI (20 μM) is administered to the ocular surface, it persistently activates YAP, which unexpectedly inhibits the de-differentiation of CECs into LESCs, demonstrating that LATS-dependent suppression of YAP is sometimes necessary for specific cellular reprogramming events [3].
Other Applications: Lats-IN-1 has also shown pharmacological utility in osteoarthritis models, where it blocks NFκB activation to prevent the upregulation of inflammatory and matrix-degrading genes under mechanical stress. Additionally, it regulates the YAP/WNT5A/FZD4 axis to promote osteogenic differentiation in human periodontal ligament cells during orthodontic tooth movement [2].
3. Molecular Mechanism of Action
TRULI functions as a direct kinase inhibitor of LATS1 and LATS2 [2]. In the canonical Hippo pathway, active LATS1/2 kinases phosphorylate YAP (e.g., at Ser112/Ser381 in mice or Ser127/Ser397 in humans), leading to its cytoplasmic sequestration and subsequent degradation [1]. By inhibiting LATS1/2, TRULI prevents this phosphorylation. Consequently, unphosphorylated YAP accumulates and translocates into the nucleus, where it acts as a transcriptional co-activator (often interacting with TEAD transcription factors) to drive the expression of downstream genes critical for cell proliferation, survival, and stem cell maintenance [1][3].
In cardiac tissue post-MI, TRULI treatment decreases the ratio of phosphorylated YAP to total YAP and phosphorylated LATS1/2 to total LATS1/2. Furthermore, this YAP activation leads to a downregulation of pro-apoptotic signaling, evidenced by decreased expression of Bax and apoptosis-executioner proteins Caspase 3 and Caspase 9 [2].
4. Structure-Activity Relationship (SAR)
The provided literature focuses extensively on the biological and therapeutic applications of TRULI (Lats-IN-1) rather than its chemical synthesis or structural optimization. Consequently, specific structure-activity relationship (SAR) data, detailing how modifications to the TRULI pharmacophore affect its binding affinity or selectivity for LATS1/2 kinases, are not described in the provided texts [1][2][3].
5. Current Limitations
Several limitations currently restrict the clinical translation and broader application of TRULI:
Lack of Comprehensive Dose-Response Data: In vivo studies utilizing TRULI are still in preliminary stages regarding pharmacokinetics and dosing. For instance, cardiac regeneration studies utilized a dose of 1 mg/kg/day based on cost and side-effect considerations, while other oncological studies have used up to 10 mg/kg. The absence of rigorous dose-response evaluations makes it challenging to ascertain the optimal therapeutic efficacy and safety profile of TRULI at different concentrations [2].
Context-Dependent Efficacy and Potential for Aberrant Plasticity: The biological outcome of LATS inhibition by TRULI is highly dependent on the tissue microenvironment. While it successfully induces proliferation in dissociated dental cells in 3D culture, YAP overactivation alone is insufficient to drive ameloblast proliferation in intact in vivo tissue due to local inhibitory signals like contact inhibition [1]. Furthermore, persistent YAP activation via TRULI can be detrimental in certain regenerative contexts, such as preventing the necessary de-differentiation of corneal epithelial cells into stem cells [3]. This highlights a risk that systemic or uncontrolled LATS inhibition could disrupt delicate cellular hierarchies or lead to hyperplasia [1].
6. Future Perspectives
TRULI (Lats-IN-1) holds significant promise as a novel therapeutic strategy for regenerative medicine, particularly for diseases characterized by irreversible cell loss, such as heart failure following myocardial infarction [2]. Future research must prioritize detailed dose-response and pharmacokinetic profiling to establish safe clinical parameters [2]. Additionally, the use of TRULI in ex vivo organoid cultures presents a powerful strategy for expanding primary somatic cells and stem cells for tissue engineering, such as in dental and craniofacial treatments [1]. Further investigations into the upstream mechanotransduction inputs and the specific microenvironmental cues that modulate Hippo/YAP signaling will be crucial. Understanding these dynamics will allow researchers to safely harness TRULI to promote targeted tissue regeneration without inducing aberrant cell fate specification or tumorigenesis [1][3].
